We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+2.81%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$628M
AUM Growth
-$105M
Cap. Flow
-$132M
Cap. Flow %
-21%
Top 10 Hldgs %
31.66%
Holding
141
New
23
Increased
28
Reduced
42
Closed
26

Top Sells

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$28.3M
2
CYTK icon
Cytokinetics
CYTK
+$8.91M
3
CRM icon
Salesforce
CRM
+$8.64M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.08M
5
ASML icon
ASML
ASML
+$6.31M

Sector Composition

Rank Sector Weight
1 Healthcare 70%
2 Technology 19.18%
3 Consumer Discretionary 3.53%
4 Communication Services 2.96%
5 Utilities 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JSPR icon
51
Jasper Therapeutics
JSPR
$21M
$3.56M 0.57%
189,270
-264,957
-58% -$5.28M
CRGX
52
DELISTED
CARGO Therapeutics
CRGX
$3.51M 0.56%
190,506
+35,000
+23% +$626K
FROG icon
53
JFrog
FROG
$9.66B
$3.5M 0.56%
120,381
+2,500
+2% +$78.5K
PLRX icon
54
Pliant Therapeutics
PLRX
$64.4M
$3.33M 0.53%
297,362
+38,808
+15% +$486K
MLYS icon
55
Mineralys Therapeutics
MLYS
$2.25B
$3.3M 0.53%
272,472
-170,280
-38% -$2.06M
ELDN icon
56
Eledon Pharmaceuticals
ELDN
$261M
$3.23M 0.51%
1,297,321
+300
+0% +$803
CGEM icon
57
Cullinan Oncology
CGEM
$1.01B
$3.11M 0.5%
+185,871
New +$3.3M
CRWD icon
58
CrowdStrike
CRWD
$194B
$3.05M 0.48%
+43,448
New +$3.09M
ZURA icon
59
Zura Bio
ZURA
$516M
$3M 0.48%
+738,718
New +$2.76M
PRAX icon
60
PUT
Praxis Precision Medicines
PRAX
$8.58B
$2.99M 0.48%
+52,000
New +$2.81M
NVDA icon
61
NVIDIA
NVDA
$4.86T
$2.96M 0.47%
24,355
+4,355
+22% +$514K
AVGO icon
62
Broadcom
AVGO
$1.85T
$2.91M 0.46%
16,880
-176,720
-91% -$28.3M
CAMT icon
63
Camtek
CAMT
$6.18B
$2.9M 0.46%
36,287
+34,347
+1,770% +$3.35M
ALEC icon
64
Alector
ALEC
$168M
$2.89M 0.46%
620,000
+10,000
+2% +$53.6K
LRMR icon
65
Larimar Therapeutics
LRMR
$397M
$2.71M 0.43%
414,478
+102,009
+33% +$820K
APLT
66
DELISTED
Applied Therapeutics
APLT
$2.65M 0.42%
311,572
-362,696
-54% -$2.14M
CYTK icon
67
CALL
Cytokinetics
CYTK
$10.5B
$2.64M 0.42%
+50,000
New +$2.79M
PFE icon
68
Pfizer
PFE
$143B
$2.6M 0.41%
90,000
ENLT icon
69
Enlight Renewable Energy
ENLT
$11.8B
$2.57M 0.41%
151,860
-17,420
-10% -$279K
IONS icon
70
Ionis Pharmaceuticals
IONS
$8.6B
$2.56M 0.41%
63,821
-76,417
-54% -$3.56M
GLBE icon
71
Global E Online
GLBE
$6.6B
$2.47M 0.39%
64,384
-2,500
-4% -$88K
VTGN icon
72
VistaGen Therapeutics
VTGN
$9.89M
$2.43M 0.39%
808,550
PMN icon
73
ProMIS Neurosciences
PMN
$123M
$2.41M 0.38%
77,172
+4,603
+6% +$172K
TVTX icon
74
CALL
Travere Therapeutics
TVTX
$5.2B
$2.39M 0.38%
+170,700
New +$1.78M
SVRA icon
75
Savara
SVRA
$1.12B
$2.39M 0.38%
563,107
-399,580
-42% -$1.76M

Similar funds

Sphera Funds Management's Q3 2024 Portfolio in Review

As of Q3 2024, Sphera Funds Management held 141 positions worth $628M, down 14% from $733M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Sphera Funds Management withdrew a net $132M in Q3 2024, closing 26 positions and reducing 42 holdings. Its most notable exit was Salesforce, an estimated $8.64M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 59% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in Nova worth $10.8M.

  • Sphera Funds Management's largest Q3 2024 buy was Nova: 51,960 shares worth $10.8M.
  • Sphera Funds Management added most to Teva Pharmaceuticals in Q3 2024, an estimated $23.5M increase.
  • Sphera Funds Management's biggest Q3 2024 reduction was Broadcom, cutting an estimated $28.3M.
  • Sphera Funds Management fully exited Salesforce in Q3 2024, selling an estimated $8.64M.
  • Sphera Funds Management's ten largest holdings make up 32% of its $628M portfolio in Q3 2024.
  • Sphera Funds Management opened 23 new positions and closed 26 in Q3 2024.
  • Sphera Funds Management's portfolio value fell 14% quarter-over-quarter to $628M.

Based on Sphera Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.